Co-targeting of HMG-Co-A Reductase and Cycloxygenase-2 for the Treatment of Non-small Cell Lung Cancer
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Juarez D, Fruman D
. Targeting the Mevalonate Pathway in Cancer. Trends Cancer. 2020; 7(6):525-540.
PMC: 8137523.
DOI: 10.1016/j.trecan.2020.11.008.
View
2.
Moon S, Huang C, Houlihan S, Regunath K, Freed-Pastor W, Morris 4th J
. p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression. Cell. 2018; 176(3):564-580.e19.
PMC: 6483089.
DOI: 10.1016/j.cell.2018.11.011.
View
3.
Frantzi M, Latosinska A, Mokou M, Mischak H, Vlahou A
. Drug repurposing in oncology. Lancet Oncol. 2020; 21(12):e543.
DOI: 10.1016/S1470-2045(20)30610-0.
View
4.
Shi G, Li D, Fu J, Sun Y, Li Y, Qu R
. Upregulation of cyclooxygenase-2 is associated with activation of the alternative nuclear factor kappa B signaling pathway in colonic adenocarcinoma. Am J Transl Res. 2015; 7(9):1612-20.
PMC: 4626422.
View
5.
Wu J, Lin Z
. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. Int J Mol Sci. 2022; 23(23).
PMC: 9738331.
DOI: 10.3390/ijms232315056.
View